Please use this identifier to cite or link to this item: http://repository.kln.ac.lk/handle/123456789/26789
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeerasekera, C.J.-
dc.contributor.authorMenike, C.W.-
dc.contributor.authorWimalasiri, U.-
dc.contributor.authorWijerathna, T.-
dc.contributor.authorJayathilake, D.C.C.-
dc.contributor.authorSomawardane, U.A.B.P.-
dc.contributor.authorSaravanamuttu, U.-
dc.contributor.authorYoganathan, N.-
dc.contributor.authorPerera, N.-
dc.contributor.authorGunathilaka, N.-
dc.contributor.authorde Silva, N.R.-
dc.contributor.authorWickremasinghe, D.R.-
dc.date.accessioned2023-10-25T07:25:04Z-
dc.date.available2023-10-25T07:25:04Z-
dc.date.issued2023-
dc.identifier.citationSri Lanka Medical Association, 136th Anniversary International Medical Congress. 2023; 68 (Supplement S):S103en_US
dc.identifier.issn0009-0875-
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/26789-
dc.descriptionPoster Presentation Abstract (PP 051), 136th Anniversary International Medical Congress, Sri Lanka Medical Association, 25th-28th July 2023, Colombo, Sri Lankaen_US
dc.description.abstractINTRODUCTION: Strongyloides stercoralis can cause severe disease in the immunocompromised. Without a proper gold-standard diagnostic technique, strongyloidiasis is scarcely studied both globally and locally. OBJECTIVES: We aimed to estimate the prevalence of strongyloidiasis among immunocompromised adult patients and to identify risk factors. METHODS: This study was carried out between February to October 2022. A faecal sample and 2 ml of venous blood were collected from consented patients. Direct faecal smear, agar plate, Harada-Mori and Charcoal cultures were performed on the faecal samples. Qualitative Polymerase Chain Reaction (PCR) was performed on selected faecal samples using S. stercoralis targeting ITS1 region. Strongyloides IgG ELISA was carried out on the serum samples using DRG Strongyloides IgG ELISA kit. RESULTS: Collectively, 144 patients (males = 68, females = 76) provided blood/faecal sample or both. Relevant to strongyloidiasis-associated symptoms, some patients had diarrhoea (n=12) and eosinophilia (n=11). Some of them (n=74) had occupational or recreational exposure to soil as potential risk factors. Overall, 24 patients were positive for strongyloidiasis from one or more diagnostic method (5 PCR and 19 ELISA). There were zero culture or direct smear positives. There was no significant association between disease positivity with either of the clinical features or risk factors. CONCLUSION: The prevalence of strongyloidiasis in patients with malignancies was 16.66%. Strongyloidiasis is existent in the immunocompromised in Sri Lanka even in the absence of suggestive clinical features or regular exposure to risk factors. Screening immunocompromised patients with sensitive techniques such as PCR for timely diagnosis and treatment is recommended.en_US
dc.language.isoenen_US
dc.publisherSri Lanka Medical Associationen_US
dc.subjectimmunocompromiseden_US
dc.subjectneglected tropical diseasesen_US
dc.subjectparasitic diseaseen_US
dc.titleThe presence of strongyloidiasis and associated risk factors in patients undergoing treatment at the National Cancer Institute, Maharagama, Sri Lankaen_US
dc.typeArticleen_US
Appears in Collections:Conference Papers

Files in This Item:
File Description SizeFormat 
Abstract-book-2023-FINAL-VERSION-2.0-103.pdf519.1 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.